News | December 27, 2012

Cardiosonic Closes $6.1 Million in Financing For Renal Denervation System

December 27, 2012 — Cardiosonic Inc., a private developer of technology in the field of renal denervation for the treatment of hypertension, announced it has closed on the first $6.1 million of a planned $16.1 million Series B financing. The round was led by a new strategic investor and joined by existing investor Shmuel Almagor. In addition the company announced that Michael Berman, an industry executive, has invested in the company and joined the board of directors as its chairman.

Cardiosonic has successfully developed a high intensity, non-focused therapeutic ultrasound catheter and control system for remote tissue ablation for the treatment of hypertension by renal denervation (RDN). The TIVUS system, which recently initiated a pilot human clinical trial, has been designed to enable quick controlled RDN without damaging the arterial endothelium.

“The TIVUS system has great potential to improve the process and outcomes of RDN procedures. In addition the TIVUS system may expand the population of patients eligible for RDN therapy by obviating current anatomic and physiologic restrictions and contraindications,” said Krishna Rocha-Singh, Prairie Heart Institute, St. John’s Hospital, Springfield, Ill., an advisor to the company.

“We are pleased to complete this financing with our new strategic partner and will rapidly move forward with our extensive clinical trial and next-generation product development plans. We anticipate rapid enrollment in multiple clinical trial protocols during the next 18 months and in parallel expect to achieve important regulatory and product development milestones,” said Cardiosonic CEO Benny Dilmoney. “We expect to become a serious competitor in the large and growing RDN international markets and be poised to execute our U.S. IDE [investigational device exemption] trial in 2014. The addition of a new strategic investor combined with the continuing commitment of our present investors is a testament to the significant progress we have made in the development and investigation of our TIVUS system.”

For more information: www.cardiosonic.co.il

Related Content

Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Text Messaging Could Help Tackle High Blood Pressure in At-Risk Patients

Image courtesy of Michigan Medicine

News | Hypertension| September 06, 2017
A new National Institutes of Health-funded hypertension trial will examine the possibility of using an emergency...
SPYRAL HTN-OFF MED Study Results Show Efficacy, Safety of Renal Denervation
News | Renal Denervation| August 31, 2017
Medtronic plc announced its intent to move forward with a new renal denervation pivotal trial following positive first...
MobiusHD Device Shows Promise in Treatment of Resistant Hypertension
News | Hypertension| August 30, 2017
Vascular Dynamics Inc. announced interim results of the company’s first-in-human trial of its MobiusHD implant...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Bayer Now Enrolling Patients for Global Pulmonary Arterial Hypertension Study
News | Hypertension| July 05, 2017
Bayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of riociguat in patients...
USC Study Finds Potassium-Rich Diet Can Lower Blood Pressure
News | Hypertension| April 19, 2017
Eating potassium-rich foods like sweet potatoes, avocados, spinach, beans, bananas and even coffee could be key to...
Vascular Dynamics Completes $10.4 Million Financing for MobiusHD System
News | Hypertension| April 13, 2017
Vascular Dynamics Inc. (VDI) a privately held medical device company developing novel solutions for the treatment of...
online lifestyle intervention, systolic blood pressure, hypertension, ACC.17, clinical study
News | Hypertension| March 27, 2017
Participants in Web-based lifestyle counseling reduced their systolic blood pressure by 10 mmHg, compared with a 6 mmHg...
News | Hypertension| February 13, 2017
Vascular Dynamics Inc. (VDI) announced that the U.S. Food and Drug Administration (FDA) has approved the company’s...
Overlay Init